Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009123 | 1.00 | HCAR2 (0.39) | HCAR2NFE2L2KEAP1GAASMN1; SMN2 | |
| SCHEMBL18009125 | 1.00 | HCAR2 (0.39) | HCAR2NFE2L2KEAP1GAASMN1; SMN2 | |
| SCHEMBL18007465 | 0.92 | GAA (0.39) | HCAR2GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18007464 | 0.92 | GAA (0.39) | HCAR2GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18009344 | 0.92 | GAA (0.39) | HCAR2GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18009089 | 0.88 | HCAR2 (0.47) | HCAR2SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL17969458 | 0.88 | HCAR2 (0.42) | HCAR2GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17966450 | 0.88 | HCAR2 (0.42) | HCAR2GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18202758 | 0.87 | LMNA (0.32) | HCAR2NFE2L2KEAP1GAASMN1; SMN2 | |
| SCHEMBL18009095 | 0.84 | HTT (0.34) | HCAR2GAASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630934-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630934-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016127186-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885NFE2L2 399/4885KEAP1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.